Litifilimab
Based on 1 Customer Validation
Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2. Litifilimab induces internalization of BDCA2 receptors on the membrane of plasmacytoid dendritic cells, inhibits the TLR7/TLR9 signaling pathway, and suppresses the production of type I interferons. Litifilimab can be used in the research of systemic and cutaneous lupus erythematosus.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.51%
- CAS 番号: 2407378-48-5
- 分子量:146.6 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 kappa
Human
|
BDCA2 |
Dectin-1 |
Litifilimab inhibits type I interferon production by plasmacytoid dendritic cells via BDCA2 binding and internalization, with dose-dependent duration of receptor internalization[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized CLEC4C Protein, Human can bind Litifilimab. The EC50 for this effect is 19.73 ng/mL.
化学情報
-
CAS 番号 2407378-48-5
-
性状 Liquid
-
分子量 146.6 kDa
-
Color Colorless to light yellow
-
SMILES
[Litifilimab]
-
別名
BIIB059
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)